178 related articles for article (PubMed ID: 23361872)
1. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA; Geddie WR; Boerner SL; Bailey D; Crump M; da Cunha Santos G
Cancer Cytopathol; 2013 Jul; 121(7):377-86. PubMed ID: 23361872
[TBL] [Abstract][Full Text] [Related]
2. Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.
Santos Gda C; Saieg MA; Ko HM; Geddie WR; Boerner SL; Craddock KJ; Crump M; Bailey D
Cancer Cytopathol; 2015 Jul; 123(7):413-20. PubMed ID: 25807917
[TBL] [Abstract][Full Text] [Related]
3. Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.
Cetin GO; Baris IC; Caner V; Sarikepe B; Sen Turk N; Tepeli E; Hacioglu S; Sari I; Bagci G; Keskin A
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):830-6. PubMed ID: 27010137
[TBL] [Abstract][Full Text] [Related]
4. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
[TBL] [Abstract][Full Text] [Related]
5. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.
Ryan RJ; Nitta M; Borger D; Zukerberg LR; Ferry JA; Harris NL; Iafrate AJ; Bernstein BE; Sohani AR; Le LP
PLoS One; 2011; 6(12):e28585. PubMed ID: 22194861
[TBL] [Abstract][Full Text] [Related]
6. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
7. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
Yonese I; Takase H; Yoshimori M; Onozawa E; Tsuzura A; Miki T; Mochizuki M; Miura O; Arai A
Eur J Haematol; 2019 Feb; 102(2):191-196. PubMed ID: 30390359
[TBL] [Abstract][Full Text] [Related]
8. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
Alcaide M; Yu S; Bushell K; Fornika D; Nielsen JS; Nelson BH; Mann KK; Assouline S; Johnson NA; Morin RD
Clin Chem; 2016 Sep; 62(9):1238-47. PubMed ID: 27440511
[TBL] [Abstract][Full Text] [Related]
9. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.
Capello D; Gloghini A; Martini M; Spina M; Tirelli U; Bertoni F; Rinaldi A; Morra E; Rambaldi A; Sinigaglia F; Larocca LM; Carbone A
Br J Haematol; 2011 Mar; 152(6):777-80. PubMed ID: 21275949
[No Abstract] [Full Text] [Related]
10. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
11. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
13. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
14. EZH2 mutations are frequent and represent an early event in follicular lymphoma.
Bödör C; Grossmann V; Popov N; Okosun J; O'Riain C; Tan K; Marzec J; Araf S; Wang J; Lee AM; Clear A; Montoto S; Matthews J; Iqbal S; Rajnai H; Rosenwald A; Ott G; Campo E; Rimsza LM; Smeland EB; Chan WC; Braziel RM; Staudt LM; Wright G; Lister TA; Elemento O; Hills R; Gribben JG; Chelala C; Matolcsy A; Kohlmann A; Haferlach T; Gascoyne RD; Fitzgibbon J
Blood; 2013 Oct; 122(18):3165-8. PubMed ID: 24052547
[TBL] [Abstract][Full Text] [Related]
15. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.
Khode R; Larsen DA; Culbreath BC; Parrish S; Walker KL; Sayage-Rabie L; Beissner RS; Rao A
Cancer Cytopathol; 2013 Jul; 121(7):361-9. PubMed ID: 23364874
[TBL] [Abstract][Full Text] [Related]
17. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
[TBL] [Abstract][Full Text] [Related]
18. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
Tian X; Pelton A; Shahsafaei A; Dorfman DM
Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
[TBL] [Abstract][Full Text] [Related]
20. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.
van Kemenade FJ; Raaphorst FM; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
Blood; 2001 Jun; 97(12):3896-901. PubMed ID: 11389032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
